Who is Miles Wang and what is his background?

Miles Wang is an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery. He joined OpenAI in 2024 after dropping out from Harvard, where he was studying for a bachelor's degree in computer science. At OpenAI, he co-authored research papers evaluating how AI models can automate and accelerate scientific discovery.

How much funding is the startup raising and at what valuation?

Wang is in talks to raise about $200 million（約320億円） at a $2 billion（約3200億円） valuation, with Lightspeed in discussions to lead the funding round. However, Wang disputed these figures, and talks are ongoing with the deal potentially subject to change.

What is the startup's focus and why is it significant?

The startup is developing AI models for drug discovery, potentially focusing on finding new uses for existing FDA-approved drugs. Finding new uses for approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

AI in HealthcareAI Business & IndustryTechCrunch AIJul 15, 2026Jul 15, 2026, 10:01 JST3 min read

OpenAI researcher Miles Wang raises $200M at $2B for AI drug discovery startup

Send on LINE

Key takeaway

Miles Wang, an OpenAI researcher working on AI for scientific discovery, is launching a new startup focused on AI drug discovery with a $2 billion（約3200億円） target valuation and roughly $200 million（約320億円） in funding discussions, led by Lightspeed.
The move comes amid significant investor interest in AI for life sciences, with comparable startups like Chai Discovery and Isomorphic Labs recently raising hundreds of millions at multibillion-dollar valuations.

3 Key Points

What happened
Miles Wang, an OpenAI researcher, is leaving to launch a startup focused on AI models for drug discovery. He is in talks to raise about $200 million（約320億円） at a $2 billion（約3200億円） valuation, with Lightspeed in discussions to lead the funding round; several other OpenAI researchers are expected to join.
Why it matters
The move reflects investor appetite for AI applied to life sciences. Comparable startups have raised substantial funding—Chai Discovery announced a $400 million（約640億円） raise at a $3.8 billion（約6100億円） valuation this week, and Google DeepMind's Isomorphic Labs raised a $2.1 billion（約3400億円） Series B in May. The new company may focus on finding new uses for existing FDA-approved drugs, which can reach revenue faster than developing drugs from scratch.
What to watch
Wang, who joined OpenAI in 2024 after dropping out from Harvard, has co-authored research on how AI models can automate and accelerate scientific discovery. Wang disputed the reported funding figures and company description but did not specify the correct details; talks are ongoing and the deal may not be final.

Ask the AI about this article →

Summaries like this, in your inbox every morning.

Get news like this every morning — free

Context & Analysis

The news reveals a significant talent exodus from OpenAI to the biotech AI sector, where investor capital is flowing robustly. Wang's departure follows a well-trodden path—another drug-discovery AI founder, Josh Meier of Chai Discovery, also passed through OpenAI as a researcher. The funding environment for AI-applied life sciences appears exceptionally strong: Chai Discovery's Tuesday announcement of a $400 million（約640億円） raise at a $3.8 billion（約6100億円） valuation and Isomorphic Labs' $2.1 billion（約3400億円） Series B in May demonstrate investor conviction that AI models can unlock drug discovery breakthroughs. The specific advantage Wang's startup may pursue—repurposing existing drugs and reviving failed candidates—avoids the lengthy clinical trial timelines that plague drug development from scratch, a distinction the article emphasizes.

Wang's profile (a 2024 hire who dropped out of Harvard for OpenAI, now launching at age and experience that once would have deterred VCs) also signals a broader shift in investor risk appetite toward young founders without traditional credentials. The fact that Wang has disputed the reported figures while declining to specify correct numbers adds a layer of uncertainty, though the involvement of Lightspeed and the cited precedent of similarly valued startups suggest the reported magnitude is plausible.

FAQ

Who is Miles Wang and what is his background?: Miles Wang is an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery. He joined OpenAI in 2024 after dropping out from Harvard, where he was studying for a bachelor's degree in computer science. At OpenAI, he co-authored research papers evaluating how AI models can automate and accelerate scientific discovery.
How much funding is the startup raising and at what valuation?: Wang is in talks to raise about $200 million（約320億円） at a $2 billion（約3200億円） valuation, with Lightspeed in discussions to lead the funding round. However, Wang disputed these figures, and talks are ongoing with the deal potentially subject to change.
What is the startup's focus and why is it significant?: The startup is developing AI models for drug discovery, potentially focusing on finding new uses for existing FDA-approved drugs. Finding new uses for approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

TechCrunch AIRead Original Article

Send on LINE